Undertreatment of patients with Alzheimer's disease in an elderly United States population

Alzheimer's and Dementia

Volumn 1, Issue 2, 2005, Pages 136-144

  Sano, Mary ^a   Amatniek, Joan ^b   Feely, Morgan ^c   Sinyak, Feliks ^d   Holton, Denise ^b   Ascher, Steve ^e   Finkel, Sanford I ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d Torrance Clinical Research   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

AChEI; Alzheimer's disease; Mild to moderate; Population; Therapy; Undertreatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; VITAMIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CLINICAL TRIAL; COMMUNITY CARE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DRUG APPROVAL; EDUCATION; ETHNIC GROUP; FEMALE; GASTROESOPHAGEAL REFLUX; GERIATRIC CARE; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH SURVEY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL SPECIALIST; NEUROLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PHYSICIAN; POPULATION RESEARCH; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

EID: 33644789340     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2005.09.011     Document Type: Article

References (36)

1. D.A. Evans Estimated prevalence of Alzheimer's disease in the United States Milbank Q 68 1990 267-289
2. R. Brookmeyer S. Gray C. Kawas Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset Am J Public Health 88 1998 1337-1342
3. L.E. Hebert P.A. Scherr J.L. Bienias D.A. Bennett D.A. Evans Alzheimer disease in the US population Arch Neurol 60 2003 1119-1122
4. P.T. Francis A.M. Palmer M. Snape G.K. Wilcock The cholinergic hypothesis of Alzheimer's disease A review of progress J Neurol Neurosurg Psychiatry 66 1999 137-147
5. A. Maelicke Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease Dement Geriatr Cogn Disord 11 suppl 1 2000 11-18
6. M.A. Raskind E.R. Peskind T. Wessel W. Yuan Galantamine in AD A 6-month randomized, placebo-controlled trial with a 6-month extension Neurology 54 2000 2261-2268
7. P.N. Tariot P.R. Solomon J.C. Morris P. Kershaw S. Lilienfeld C. Ding A 5-month, randomized, placebo-controlled trial of galantamine in AD Neurology 54 2000 2269-2276
8. G.K. Wilcock S. Lilienfeld E. Gaens Galantamine International-1 Study Group Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease Multicentre randomised controlled trial BMJ 321 2000 1445-1449
9. K. Rockwood J. Mintzer L. Truyen T. Wessel D. Wilkinson Effects of a flexible galantamine dose in Alzheimer's disease A randomised, controlled trial J Neurol Neurosurg Psychiatry 71 2001 589-595
10. S.L. Rogers M.R. Farlow R.S. Doody R. Mohs L.T. Friedhoff Donepezil Study Group A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease Neurology 50 1998 136-145
11. S.L. Rogers R.S. Doody R.C. Mohs L.T. Friedhoff Donepezil Study Group Donepezil improves cognition and global function in Alzheimer disease A 15-week, double-blind, placebo-controlled study Arch Intern Med 158 1998 1021-1031
12. R.C. Mohs R.S. Doody J.C. Morris J.R. Ieni S.L. Rogers C.A. Perdomo "312" Study Group A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients Neurology 57 2001 481-488
13. J. Corey-Bloom R. Anand J. Veach ENA 713 B352 Study Group A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease Int J Geriatr Psychopharmacol 1 1998 55-65
14. M. Rösler R. Anand A. Cicin-Sain S. Gauthier Y. Agid P. Dal Bianco et. al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease International randomised controlled trial BMJ 318 1999 633-640
15. B.P. Leifer Early diagnosis of Alzheimer's disease Clinical and economic benefits J Am Geriatr Soc 51 5 suppl Dementia 2003 S281-S288
16. H. Fillit J. Cummings Alzheimer's Disease Managed Care Advisory Council Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting part II-pharmacologic therapy Manag Care Interface 13 2000 51-56
17. R.S. Doody J.C. Stevens C. Beck R.M. Dubinsky J.A. Kaye L. Gwyther et. al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 56 2001 1154-1166
18. G. McKhann D. Drachman M. Folstein R. Katzman D. Price E.M. Stadlan Clinical diagnosis of Alzheimer's disease Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939-944
19. M.F. Folstein S.E. Folstein P.R. McHugh "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189-198
20. C. Kawas S. Gray R. Brookmeyer J. Fozard A. Zonderman Age-specific incidence rates of Alzheimer's disease The Baltimore Longitudinal Study of Aging Neurology 54 2000 2072-2077
21. Federal Interagency Forum on Aging-Related Statistics. Older Americans 2000: Key Indicators of Well-Being. AvWilable at: www.aoa.gov/agingstats/ chartbook2000/population.html. Accessed April 22, 2003.
22. G.P. Wolf-Klein F.A. Siverstone M.S. Brod A. Levy C.J. Foley V. Termotto et. al. Are Alzheimer patients healthier? J Am Geriatr Soc 36 1988 219-224
23. M. Sanderson J. Wang D.R. Davis M.J. Lane C.B. Cornman M.K. Fadden Co-morbidity associated with dementia Am J Alzheimers Dis Other Demen 17 2002 73-78
24. Centers for Disease Control and Prevention Summary Health Statistics for U.S. Adults National Health Interview Survey, 1998 2002 Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics Hyattsville, Md DHHS Publication No. (PHS) 2003-1537.
25. D.W. Kaufman J.P. Kelly L. Rosenberg T.E. Anderson A.A. Mitchell Recent patterns of medication use in the ambulatory adult population of the United States the Slone survey JAMA 287 2002 337-344
26. Centers for Disease Control and Prevention National Health and Nutrition Examination Survey Patterns of Prescription Drug Use in the United States 1988-94 Available at: www.cdc.gov/nchs/data/nhanes/databriefs/ preuse.pdf. Accessed April 18, 2003
27. D.P. Devanand D.M. Jacobs M.X. Tang C. Del Castillo-Castaneda M. Sano K. Marder et. al. The course of psychopathologic features in mild to moderate Alzheimer disease Arch Gen Psychiatry 54 1997 257-263
28. D. Galasko An integrated approach to the management of Alzheimer's disease Assessing cognition, function and behaviour Eur J Neurol 5 suppl 4 1998 S9-S17
29. R. Stone G.L. Cafferata J. Sangl Caregivers of the frail elderly A national profile Gerontologist 27 1987 616-626
30. F.H. Steffensen H.T. Sørensen F. Olesen Diffusion of new drugs in Danish general practice Fam Pract 16 2004 407-413
31. C.E. Mann M.J. Himelein Factors associated with stigmatization of persons with mental illness Psychiatr Serv 55 2004 185-187
32. J.C. Morris Is Alzheimer's disease inevitable with age? Lessons from clinicopathologic studies of healthy aging and very mild Alzheimer's disease J Clin Invest 104 1999 1171-1173
33. D. Grady Minimal benefit is seen in drugs for Alzheimer's The New York Times 2004 April 7,. Available at: http://www.query.nytimes.com/search/advanced.
34. C. Courtney D. Farrell R. Gray R. Hills L. Lynch E. Sellwood et. al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000) Randomized double-blind trial Lancet 363 2004 2105-2115
35. M. Sano G.K. Wilcock B. Van Baelen S. Kavanagh The effects of galantamine treatment on caregiver time in Alzheimer's disease Int J Geriatr Psychiatry 18 2003 942-950
36. World Health Organization WHO Drug Dictionary 1999 Maintained by the Uppsala Monitoring Center Uppsala, Sweden